GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Agenus
Agenus is a biopharmaceutical company with a broad pipeline in immuno-oncology. Its stock price reflects both the potential of its own drugs and the success of its partners using its technologies, creating a diversified yet risky profile.
Share prices of companies in the market segment - Pharma immune
Agenus Inc. is an immuno-oncology company with a broad development pipeline, including checkpoint inhibitors, cell therapy, and cancer vaccines. We classify it as a Pharmaceuticals (Immunology) company, where it is a leading innovator. The chart below illustrates the dynamics of this highly competitive and research-intensive sector.
Broad Market Index - GURU.Markets
Agenus is an immuno-oncology company with a broad pipeline, including checkpoint inhibitors and cancer vaccines. Its diversified approach makes it a component of the GURU.Markets index. The chart below compares its performance to the broader market.
Change in the price of a company, segment, and market as a whole per day
AGEN - Daily change in the company's share price Agenus
Change_co for Agenus, an immuno-oncology company, measures its high volatility. It reflects sensitivity to clinical trial results and partnerships. This metric is important for biotech sector analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
Agenus Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with AGEN's performance, with its broad development portfolio, helps assess how diversification impacts its risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Agenus is a biotech company with a broad pipeline of immuno-oncology developments. Its shares react to news across multiple clinical programs. This complex, multi-factor dynamic contributes uniquely to the overall volatility of the healthcare sector and the overall market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Agenus
Agenus Inc.'s year-over-year performance tells the story of its extensive and complex immuno-oncology pipeline. Its market cap change over the past 12 months reflects both the progress of its own programs and the success of its partners. Approval of its first drug will be a fundamental confirmation of the viability of its scientific platform.
Annual dynamics of market capitalization of the market segment - Pharma immune
Agenus Inc. is a biotech company developing immunotherapies for cancer treatment. Its diversified portfolio and drug discovery platform are key strengths. The chart below shows how the market views its scientific potential and numerous partnerships.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Agenus is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor expectations for the success of its immunotherapy trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Agenus
Agenus develops immuno-oncology drugs and has a broad pipeline. Its monthly performance is a composite of news from various clinical programs and partnership revenues. Success or failure in any one area can cause significant fluctuations, making the chart a reflection of the management of this complex R&D portfolio.
Monthly dynamics of market capitalization of the market segment - Pharma immune
This chart reflects the dynamics of the volatile biotech sector. For Agenus, with its broad development pipeline, it's the backdrop. Its movements show how the successes and failures of numerous clinical trials and partnerships influence investor sentiment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Agenus is a biopharmaceutical company developing immuno-oncology drugs, including vaccines and checkpoint inhibitors. It's a high-risk business. The overall market chart provides only background information, while Agenus's performance is driven by clinical trial news, which can trigger sharp movements counter to any market trend.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Agenus
The weekly performance of Agenus, a biopharmaceutical company developing immuno-oncology drugs, is a barometer of innovation in the fight against cancer. Share prices are volatile and respond to clinical trial data from its numerous candidates and news of partnerships with major pharmaceutical companies.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Agenus specializes in immuno-oncology, developing drugs that help the body fight cancer. This sector is highly sensitive to research data. The chart will show whether Agenus's weekly share price movements are driven by news about its developments or by the general market reaction to developments in immunotherapy.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Agenus is another biotech company focused on immuno-oncology. Its shares can be highly volatile and react to research news. This chart will help you understand whether Agenus is living in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are influencing its stock price.
Market capitalization of the company, segment and market as a whole
AGEN - Market capitalization of the company Agenus
Agenus's market capitalization chart tells the story of its years-long development of a broad portfolio of immuno-oncology drugs. Its volatile dynamics reflect both the successes and failures of numerous clinical programs. Its trajectory reflects the market's assessment of its scientific platform and the belief that one of its candidates will become a blockbuster.
AGEN - Share of the company's market capitalization Agenus within the market segment - Pharma immune
Agenus is a biopharmaceutical company developing immunotherapeutics, including checkpoint inhibitors and vaccines for cancer. Its market share reflects its broad pipeline and strategic partnerships. The chart shows how the market views its multifaceted approach to fighting cancer.
Market capitalization of the market segment - Pharma immune
Agenus is a biotech company developing a broad range of immunotherapeutic drugs to combat cancer. The chart below shows the market capitalization of this rapidly growing sector. Its dynamics reflect the global efforts and massive investments in finding ways to "train" the immune system to attack tumors.
Market capitalization of all companies included in a broad market index - GURU.Markets
Agenus develops immuno-oncology drugs that help the immune system fight cancer. The company's market capitalization is determined by its research portfolio and partnerships. Its performance on the overall chart is one of many streams feeding the larger river known as "cancer immunotherapy."
Book value capitalization of the company, segment and market as a whole
AGEN - Book value capitalization of the company Agenus
Agenus's foundation is its capital, which is dedicated to developing a broad portfolio of immuno-oncology drugs, as well as its manufacturing facilities and patents. It's a tangible, scientific conveyor belt for creating new cancer treatments. How has this diversified biotech asset evolved? The chart below shows its dynamics.
AGEN - Share of the company's book capitalization Agenus within the market segment - Pharma immune
Agenus develops immuno-oncology drugs using its own manufacturing and research capabilities. The chart shows the share of these advanced biotech assets in the pharmaceutical sector, reflecting the physical scale behind its portfolio of innovative drugs.
Market segment balance sheet capitalization - Pharma immune
Agenus develops immuno-oncology drugs, a knowledge-intensive process. Its main assets are patents and research results. The chart below shows how "light" the company's tangible asset base is, given its core value lies in science.
Book value of all companies included in the broad market index - GURU.Markets
Agenus is developing an arsenal to harness the immune system's power to fight cancer. The company's book value is derived from its antibody production facilities, research centers, and vaccine development platforms. The chart below shows the material foundation upon which the next generation of immunotherapeutics is being built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Agenus
Agenus has laboratories, but its value lies in its broad portfolio of immuno-oncology developments. The chart shows the premium the market pays for its scientific platform and the potential to develop multiple successful drugs. This is a valuation not of a single asset, but of an entire pipeline of innovations.
Market to book capitalization ratio in a market segment - Pharma immune
Agenus develops immuno-oncology drugs that support the body's immune system in fighting cancer. Its value comes from its scientific pipeline and patents. This chart shows how much investors believe in its scientific approach, valuing it significantly above its tangible assets.
Market to book capitalization ratio for the market as a whole
Agenus develops immuno-oncology therapies, including vaccines and antibodies, to stimulate a patient's immune system to fight cancer. The company's core assets are its scientific platform and development pipeline. This chart shows overall valuations, but how do investors view a biotech company that's trying to turn cancer into a manageable disease?
Debts of the company, segment and market as a whole
AGEN - Company debts Agenus
Agenus, a biotech company with a broad portfolio of immuno-oncology drugs, pursues a complex financial strategy. This chart shows how it utilizes various instruments to simultaneously fund multiple research programs. This is a diversified approach to investing in future breakthroughs in cancer treatment.
Market segment debts - Pharma immune
Agenus develops immuno-oncology therapeutics, including vaccines and antibodies, to combat cancer. With a broad pipeline, the company must allocate capital wisely. This chart shows how Agenus funds its numerous clinical programs and how its strategy compares to other biotech platforms.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Agenus
Agenus is an immuno-oncology company with a broad pipeline. This chart allows us to evaluate its financial strategy for debt management. The company can use debt to accelerate multiple clinical programs simultaneously, and this metric demonstrates the level of risk it is taking to achieve potential market leadership.
Market segment debt to market segment book capitalization - Pharma immune
Agenus develops immuno-oncology drugs that stimulate the body's immune system to fight cancer. This chart shows the overall debt burden in the immunopharmaceuticals sector. It helps understand how the industry finances its extensive clinical programs and how Agenus, with its broad development pipeline, manages its balance sheet.
Debt to book value of all companies in the market
Agenus develops immuno-oncology drugs, a long and capital-intensive process. Such companies often raise equity rather than debt. This chart, showing the market's total debt load, illustrates how Agenus's venture-focused financing strategy differs from the overall economic environment.
P/E of the company, segment and market as a whole
P/E - Agenus
This chart for Agenus, an immuno-oncology company with a broad pipeline, shows how investors value its platform approach. The multiple reflects the combined expectations of multiple clinical programs and potential partnerships, not the success of a single product. It's an assessment of the company's long-term scientific and commercial strategy.
P/E of the market segment - Pharma immune
Immuno-oncology, where Agenus is an innovator, is at the forefront of the fight against cancer. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Agenus, with its broad portfolio of proprietary and partnered developments, is considered a diversified scientific platform with a strong chance of success.
P/E of the market as a whole
Agenus Inc. is an immuno-oncology company with a broad pipeline, including checkpoint inhibitors and cancer vaccines. A diversified approach mitigates risk. This overall investment climate chart provides insight into how the market views this platform model compared to companies focused on a single drug, given overall market sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Agenus
Agenus develops immuno-oncology drugs, including vaccines and antibodies to fight cancer. This chart reflects the market's complex expectations for its broad pipeline. The dynamics show how investors assess the likelihood of success for various clinical programs and potential partnerships with pharma giants.
%20P%2FE%20Agenus&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Agenus&v=1772513658012 "Chart of the company's future (projected) P/E Agenus")
Future (projected) P/E of the market segment - Pharma immune
Agenus develops immuno-oncology drugs, including checkpoint inhibitors and cancer vaccines. This chart shows average profitability expectations for the sector. It allows investors to assess how Agenus's R&D platform and its ability to develop combination therapies compare to other biotech companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772513658032 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Agenus Inc. is a biotech company focused on immuno-oncology, developing vaccines and drugs that activate the immune system to fight cancer. This chart demonstrates investor appetite for innovation. For a company with a broad pipeline, it reflects the market's willingness to invest in platform solutions with long-term potential.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513658058 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Agenus
Agenus is an immuno-oncology company with a broad pipeline, including checkpoint inhibitors and cancer vaccines. The financial results shown here are a combination of expenses from numerous clinical programs and partnership revenues. The chart reflects the complexity and cost of developing a comprehensive cancer treatment strategy.
Profit of companies in the market segment - Pharma immune
Agenus is an immuno-oncology company developing drugs that activate the immune system to fight cancer. Its portfolio includes checkpoint inhibitors and vaccines. This chart shows the overall profitability dynamics in the biotech sector, where innovative immunotherapy approaches like Agenus's are one of the main growth drivers.
Overall market profit
Agenus develops immuno-oncology drugs aimed at stimulating the body's own immune system to fight cancer. This is a capital-intensive industry that requires years of research. A favorable economic environment, reflected in this chart, is crucial for Agenus, as it provides access to funding and the opportunity to partner with major pharmaceutical companies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Agenus
Agenus is an immuno-oncology company with a broad pipeline, including checkpoint inhibitors and cancer vaccines. The earnings forecast shown in the chart reflects analysts' expectations for the success of clinical trials, potential partnerships, and future sales of its drugs. This is an assessment of the company's entire promising pipeline.
%20profit%20of%20the%20company%20Agenus&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Agenus&v=1772513658222 "Graph of future (projected) profit of the company Agenus")
Future (predicted) profit of companies in the market segment - Pharma immune
Agenus develops immuno-oncology therapies, including checkpoint inhibitors and vaccines, to harness the patient's own immune system to fight cancer. This chart shows the revenue forecast for the immune pharmaceuticals sector, allowing us to assess how Agenus' pipeline aligns with overall growth and profitability expectations for the sector.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772513658277 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Agenus is an immuno-oncology company developing drugs to fight cancer. Its success depends on progress in clinical trials and the ability to fund R&D. This schedule, reflecting investors' risk appetite, influences the overall capital flow into the biotech sector, which determines Agenus's future.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513658298 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Agenus
Agenus develops immuno-oncology therapies, including vaccines and antibodies, to stimulate the immune system to fight cancer. This chart reflects investor valuations of its broad and diverse pipeline. Revenue estimates represent a combined bet on the success of multiple clinical programs.
P/S market segment - Pharma immune
Agenus is an immuno-oncology company developing a broad range of cancer treatments, including checkpoint inhibitors and vaccines that activate a patient's immune system to fight tumors. This chart shows the average revenue estimate for the biotech company, helping to understand how highly investors value Agenus's diversified pipeline.
P/S of the market as a whole
Agenus is an immuno-oncology company developing a portfolio of immunotherapeutics, including antibodies and cancer vaccines. The company has both commercial and experimental products. This total market valuation chart helps understand how investors balance current and future revenue potential in the complex biotech sector.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Agenus
Agenus develops immuno-oncology drugs that stimulate the body's own immune system to fight cancer. This chart shows how the market values the company relative to its future sales. It reflects investor expectations for the success of its broad pipeline of developments, both proprietary and in partnership.
%20P%2FS%20Agenus&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Agenus&v=1772513658501 "The graph of the company's future (projected) P/S Agenus")
Future (projected) P/S of the market segment - Pharma immune
Agenus develops immuno-oncology drugs, including checkpoint inhibitors and vaccines, to stimulate the immune system to fight cancer. The company has a broad pipeline. This metric demonstrates how investors view its scientific platform and future revenue potential compared to other immunopharmaceutical companies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772513658532 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Agenus is an immuno-oncology company with a broad pipeline. Its future revenue depends on the success of clinical trials and partnerships. This general expectations chart for AGEN is not a direct driver. The company is in a sector where value is created by science. Successful drug data could drive growth contrary to any general market trends.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513658541 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Agenus
This chart shows the financial trajectory of the innovative immuno-oncology company Agenus. It reflects revenues consisting of royalties from already approved products, payments from large pharmaceutical partners for co-development, and revenues from licensing its technology platforms.
Sales of companies in the market segment - Pharma immune
Agenus develops immuno-oncology drugs, including checkpoint inhibitors and vaccines. Its broad pipeline of candidates is impacting the entire sector. This chart reflects the growth of the immunotherapy market, and Agenus's successful combinations and new drugs directly contribute to overall revenue growth, offering new options for fighting cancer.
Overall market sales
Agenus develops immuno-oncology drugs that support the body's own immune system in fighting cancer. The company is at the forefront of medical research. Its success in creating new treatments is part of the innovative drive in healthcare, which is increasingly making a significant contribution to the overall economic picture.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Agenus
Agenus develops immuno-oncology drugs, including checkpoint inhibitors and cancer vaccines. The company's future sales depend on the approval of its candidates and the success of partnerships with major pharmaceutical companies. This chart demonstrates analysts' confidence in the potential of its scientific platform.
%20sales%20of%20the%20company%20Agenus&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Agenus&v=1772513658707 "Schedule of future (projected) sales of the company Agenus")
Future (projected) sales of companies in the market segment - Pharma immune
Agenus develops immunotherapeutic drugs to fight cancer. The outlook for the immune-pharma sector reflects the enormous interest in technologies that "train" the body's immune system to attack tumors. This chart demonstrates the favorable environment for Agenus' innovative approaches and developments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772513658715 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Agenus is an immuno-oncology company developing drugs that support the immune system in fighting cancer. The company's success depends on research results and partnerships. This overall economic activity schedule does not directly impact demand, but it may impact funding for the biotech sector and the budgets of its major pharmaceutical partners.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513658734 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Agenus
Agenus is a biopharmaceutical company developing immunotherapies for cancer treatment. Its financial model is complex: it includes revenue from royalties and partnerships, which must cover the enormous costs of its own clinical research. This chart shows how successfully the company balances current revenue with investments in the future.
Market segment marginality - Pharma immune
Agenus develops immuno-oncology therapies, including vaccines and antibodies, to combat cancer. Profitability depends on the success of clinical programs and partnerships. This chart shows the operating efficiency of its scientific platform and cost structure compared to other companies working in the immunotherapy field.
Market marginality as a whole
Agenus Inc. is an immuno-oncology company developing drugs that help the immune system fight cancer. This chart shows the overall profit margin. It illustrates the complex biotech model: not only does Agenus conduct its own research but also licenses its technologies, creating multiple potential paths to future profitability.
Employees in the company, segment and market as a whole
Number of employees in the company Agenus
Agenus is an immuno-oncology company with a broad development pipeline. Its team of scientists and researchers is working to develop next-generation anti-cancer therapies. The growth illustrated by this graph is directly related to the expansion of its clinical programs and the advancement of its candidate drugs into the next stages of testing.
Share of the company's employees Agenus within the market segment - Pharma immune
Agenus develops and commercializes immunotherapeutic drugs for the treatment of cancer. This chart reflects its scientific weight in the competitive field of immuno-oncology. It shows the significant share of immunologist, biologist, and antibody research scientists Agenus attracts to develop its broad portfolio of innovative drugs.
Number of employees in the market segment - Pharma immune
Agenus develops immuno-oncology drugs that support the body's own immune system in fighting cancer. This chart illustrates the boom in immunotherapy. The growing number of scientists and clinicians in this field is a direct result of scientific breakthroughs that have changed the treatment paradigm for many types of cancer.
Number of employees in the market as a whole
Agenus develops immuno-oncology drugs, and its market capitalization is a bet on future scientific breakthroughs. The general labor market dynamics, illustrated by this chart, have virtually no impact on the company. Headcount expansion is being undertaken for specific tasks: launching a new phase of clinical trials or building manufacturing facilities for a promising drug.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Agenus (AGEN)
Agenus is a biotech company with a broad pipeline of immuno-oncology developments, including vaccines and antibodies. This chart demonstrates a model where value is created by the intellectual labor of a team of scientists. The high market capitalization per employee suggests that the market is pricing in the potential of numerous blockbuster drugs.
%20of%20the%20company%20Agenus%20(AGEN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Agenus-AGEN&v=1772513658860 "Chart of market capitalization per employee (in thousands of dollars) of the company Agenus (AGEN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Agenus develops immuno-oncology drugs. The company's value lies in its patent portfolio and clinical trials, all of which are carried out by a relatively small team. This graph illustrates the high concentration of intellectual capital: each employee contributes to a multi-billion dollar valuation, typical of the innovative biopharmaceutical sector.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772513658865 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Agenus is an immuno-oncology company developing a broad portfolio of drugs to stimulate the immune system in the fight against cancer. This chart shows how the market values a company with a platform approach, where a single scientific idea can lead to the development of multiple products, creating high potential value per researcher.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513658886 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Agenus (AGEN)
Agenus is a biotech company developing immuno-oncology drugs (including checkpoint inhibitors). They have their own R&D platform. This chart shows how productive this platform is. It reflects how much revenue (from partnerships or sales) or loss (from R&D) is generated by each scientist working on the next generation of cancer drugs.
%20Chart%20Agenus%20(AGEN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Agenus-AGEN&v=1772513658891 "Company Profit Per Employee (in thousands of dollars) Chart Agenus (AGEN)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Agenus develops immuno-oncology treatments. This metric reflects the industry-average efficiency of staff utilization. For Agenus, with its broad development pipeline and antibody platform, it reflects the balance between high R&D costs and potential revenue from partnerships or future sales. Their goal is to monetize their scientific assets better than their competitors.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772513658906 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Agenus is a biotech company focused on immuno-oncology. Unlike many of its peers, Agenus has both commercial products and a broad pipeline of developments. This metric helps evaluate the hybrid model: how well existing sales and partnerships can cover the costs of a large scientific team working on new drugs and generate profits.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513658908 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Agenus (AGEN)
Agenus develops immuno-oncology drugs, and this chart reflects the performance of its multi-faceted platform. It shows how revenue from partnerships, licensing, and potentially early sales compares to the size of the team. This is an indicator of the company's ability to monetize its intellectual property and research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Agenus-AGEN&v=1772513658919 "Sales chart per company employee Agenus (AGEN)")
Sales per employee in the market segment - Pharma immune
Agenus develops immuno-oncology drugs (checkpoint inhibitors, cell therapies). Their business model includes both in-house development and licensing. This metric reflects how productive their R&D team is in generating revenue (royalties, affiliate fees) compared to other companies working in the immunotherapy field.
Sales per employee for the market as a whole
Agenus is a biotech company developing immunotherapeutic drugs for cancer. They have both an in-house R&D pipeline and an approved product (Botilimumab in South Korea). This chart shows revenue per employee. It reflects the effectiveness of their scientific platform in generating royalties and partner fees, as well as early commercial success, which is key to an R&D business.
Short shares by company, segment and market as a whole
Shares shorted by company Agenus (AGEN)
Agenus develops immunotherapeutics, including checkpoint inhibitors and cancer vaccines. The company has a broad, albeit early, pipeline. This chart indicates bearish sentiment. Bears may be concerned about high capital burn, intense competition in the immuno-oncology field, and the risk of failure in clinical trials funded by partnerships.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Agenus-AGEN&v=1772513658939 "Short Shares Chart for the Company Agenus (AGEN)")
Shares shorted by market segment - Pharma immune
Agenus develops immunotherapeutic drugs, including checkpoint inhibitors, for the treatment of cancer. This chart shows overall short positions across the biotech sector. The high short interest in the industry reflects general investor skepticism about the sector, possibly due to recent clinical trial setbacks or pricing concerns.
Shares shorted by the overall market
Agenus (AGEN) is a clinical-stage biotech company working in immuno-oncology. Its survival depends on access to funding. When this market pessimism indicator rises, the window for raising capital slams shut. Investors panic and flee unprofitable, speculative ventures like AGEN.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Agenus (AGEN)
Agenus is a biotech company developing cancer immunotherapy. The stock is volatile and dependent on R&D and partnerships. This chart reading above 70 may reflect positive trial data or new deals. Oversold territory (<30) is often associated with research setbacks or funding concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Agenus-AGEN&v=1772513658951 "RSI 14 indicator chart for the company's stock Agenus (AGEN)")
RSI 14 Market Segment - Pharma immune
Agenus (AGEN) is an immuno-oncology "factory." They don't *search* for, but *create* "combines" (antibodies, checkpoints) to *attack* cancer. RSI_14_Seg for "Pharma-immune" (biotech) shows the overall sentiment. The chart helps us understand: is AGEN's volatility just their R&D platform, or is the *entire* sector "overheated"?
RSI 14 for the overall market
Agenus (AGEN) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AGEN (Agenus)
Agenus (AGEN) is an immuno-oncology company developing a portfolio of drugs (including botensilimab) that "train" the immune system to fight cancer. This chart shows the average target price. It reflects analysts' confidence in this platform and its potential to treat various tumor types.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AGEN-Agenus&v=1772513658975 "A chart showing analyst consensus forecasts for the expected stock price. AGEN (Agenus)")
The difference between the consensus estimate and the actual stock price AGEN (Agenus)
Agenus is an immuno-oncology company with a broad development pipeline. It develops both proprietary drugs and cancer vaccines. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their "aggregate" assessment of this extensive but early R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AGEN-Agenus&v=1772513658980 "A chart showing the difference between the consensus forecast and the actual stock price. AGEN (Agenus)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Agenus (AGEN) is an immuno-oncology company developing checkpoint inhibitors (like Keytruda, but its own) and cancer vaccines. This chart shows analysts' overall expectations for the immunotherapy sector. It reflects whether experts believe in the company's extensive R&D pipeline and its ability to compete with Big Pharma.
Analysts' consensus forecast for the overall market share price
Agenus (AGEN) is a biotech company specializing in immuno-oncology. They have a broad pipeline, including checkpoints and cancer vaccines. This chart shows overall market sentiment. For Agenus, with their diversified but risky R&D, it's important to understand how risk appetite (sentiment) influences their portfolio valuation. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Agenus
Agenus is a platform biotech. They don't bet everything on one gamble, but rather develop a wide range of immuno-oncology drugs (antibodies, adjuvants), which they either develop in-house or license to large pharma partners. This chart is a summary indicator of their complex R&D strategy. It reflects their royalties, payments from partners, and their confidence in their pipeline.
AKIMA Market Segment Index - Pharma immune
Agenus is an immuno-oncology company with a broad pipeline, including checkpoint inhibitors and cancer vaccines. This chart shows the average index for the immuno-pharma sector. It helps investors assess how promising Agenus's diversified R&D portfolio is compared to the industry average.
The AKIM Index for the overall market
Agenus is an immuno-oncology company with a broad portfolio of antibodies (Botensilimab). It is known for innovation, but also for financial challenges. This chart, reflecting the market average, is an indicator of risk appetite. It shows the macro backdrop, which is critical for funding this ambitious research program.
